Nishikawa, Yoshitaka http://orcid.org/0000-0003-3313-1990
Agatsuma, Nobukazu
Utsumi, Takahiro
Funakoshi, Taro
Mori, Yukiko
Nakamura, Yuki
Hoshino, Nobuaki
Horimatsu, Takahiro
Saito, Takumi
Kashihara, Soichiro
Fukuyoshi, Jun
Goto, Rei
Toi, Masakazu
Takahashi, Yoshimitsu
Nakayama, Takeo
Article History
Received: 31 August 2023
Accepted: 18 October 2023
First Online: 20 November 2023
Declarations
:
: Yoshitaka Nishikawa reports a donation from Datack outside the submitted work. Jun Fukuyoshi is the founder of Cancerscan Co., Ltd. Takumi Saito and Soichiro Kashihara are members of Cancerscan Co., Ltd. Masakazu Toi reports the following potential conflicts of interest outside the submitted work: grants from Chugai Pharmaceutical, Takeda Pharmaceutical, Pfizer, Taiho Pharmaceutical, JBCRG, the Kyoto Breast Cancer Research Network, Eisai, Eli-Lilly and Co., Daiichi Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI Technology, Luxonus, Shionogi, GL Science, and Sanwa Shurui; personal fees (honoraria for lecture/lecture chair) from Chugai Pharmaceutical, Takeda Pharmaceutical, Pfizer, Taiho Pharmaceutical, Eisai, Daiichi Sankyo, AstraZeneca, Eli Lilly, MSD, Exact Science, Novartis Pharma, Shimadzu, Yakult, Nippon Kayaku, Devicore Medical Japan, and Sysmex; being a member of the advisory board for Daiichi Sankyo, Eli Lilly, BMS, Athenex Oncology, Bertis, Terumo, and Kansai Medical Net; and being a member of the board of directors (unpaid) for JBCRG, the Kyoto Breast Cancer Research Network, the Organization for Oncology and Translational Research, and the Japanese Breast Cancer Society. Takeo Nakayama reports the following potential conflicts of interest outside the submitted work: grants from I&H Co., Ltd, Cocokarafine Group Co., Ltd, and Konica Minolta, Inc.; consulting fees from Ohtsuka Pharmaceutical Co., Takeda Pharmaceutical Co., and BonBon Inc.; honoraria from Pfizer Japan Inc., MSD K.K., Chugai Pharmaceutical Co., Takeda Pharmaceutical Co., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH, Eli Lilly Japan K.K., Maruho Co., Ltd, Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., Allergan Japan K.K., Novo Nordisk Pharma Ltd, Toa Eiyo Ltd, Dentsu Co., Ono Pharmaceutical Co., Ltd, GSK, Alexion Pharmaceuticals, Inc., Cannon Medical Systems Co., Kowa Company Ltd, and Araya; stock option from BonBon Inc.; and donation from Cancerscan and Yuyama Co., Ltd. All the other authors declare no competing interests.
: This project was conducted as part of Hachioji City’s public health practice in accordance with the city’s regulations. All the results of this study are publicly available on the city’s website (ExternalRef removed). As this study included solely open data, ethical approval was not required.